| Literature DB >> 30934713 |
Ruowei Guan1, Yuan Peng2, Lutan Zhou3,4, Wenqi Zheng5, Xixi Liu6, Pin Wang7, Qingxia Yuan8, Na Gao9, Longyan Zhao10, Jinhua Zhao11,12.
Abstract
Apostichopus japonicus is one of the most economically important species in sea cucumber aquaculture in China. Fucosylated glycosaminoglycan from A. japonicus (AjFG) has shown multiple pharmacological activities. However, results from studies on the structure of AjFG are still controversial. In this study, the deaminative depolymerization method that is glycosidic bond-selective was used to prepare the depolymerized products from AjFG (dAjFG), and then a series of purified oligosaccharide fragments such as tri-, hexa-, nona-, and dodecasaccharides were obtained from dAjFG by gel permeation chromatography. The 1D/2D NMR and ESI-MS spectrometry analyses showed that these oligosaccharides had the structural formula of l-FucS-α1,3-d-GlcA-β1,3-{d-GalNAc4S6S-β1,4-[l-FucS-α1,3-]d-GlcA-β1,3-}n-d-anTal-diol4S6S (n = 0, 1, 2, 3; FucS represents Fuc2S4S, Fuc3S4S, or Fuc4S). Thus, the unambiguous structure of native AjFG can be rationally deduced: it had the backbone of {-4-d-GlcA-β1,3-d-GalNAc4S6S-β1-}n, which is similar to chondroitin sulfate E, and each d-GlcA residue in the backbone was branched with a l-FucS monosaccharide at O-3. Bioactivity assays confirmed that dAjFG and nonasaccharides and dodecasaccharides from AjFG had potent anticoagulant activity by intrinsic FXase inhibition while avoiding side effects such as FXII activation and platelet aggregation.Entities:
Keywords: Apostichopus japonicus; anti-Fxase; fucosylated glycosaminoglycan; oligosaccharide; unambiguous structure
Mesh:
Substances:
Year: 2019 PMID: 30934713 PMCID: PMC6520811 DOI: 10.3390/md17040195
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Physicochemical properties of AjFG, dAjFG, and the purified fragments. HPLC profiles of AjFG (a), dAjFG (a and b) and the oligosaccharide fragments with various dp (c) (A); chromatograms of PMP derivatives of mixed monosaccharide standards (a) and AjFG (b) (B); and FI-IR spectrum of AjFG (C).
Figure 21H-13C HSQC (A) and superimposed 1H-1H COSY (black), TOCSY (red), and ROESY (green) (B) spectra of Fragment 1 (Fr-1). I and II represent type I and II of FucS, respectively. UI, UII, TI, and TII represent the GlcA and anTal-diol residues substituted with type I and II of FucS, respectively.
1H/13C NMR chemical shift assignments of Fr-1 (800 MHz, D2O).
|
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| δH (ppm) | Coupling Constant in Hz | δC (ppm) | δH (ppm) | Coupling Constant in Hz | δC (ppm) | ||||||
| TI | H-1 | 5.00 | C-1 | 91.7 | TII | H-1 | 5.00 | C-1 | 91.6 | ||
| H-2 | 3.98 | C-2 | 86.1 | H-2 | 3.99 | C-2 | 86.2 | ||||
| H-3 | 4.59 | C-3 | 78.8 | H-3 | 4.60 | C-3 | 78.4 | ||||
| H-4 |
| C-4 |
| H-4 |
| C-4 |
| ||||
| H-5 | 4.48 | C-5 | 80.4 | H-5 | 4.48 | C-5 | 80.3 | ||||
| H-6 |
| C-6 |
| H-6 |
| C-6 |
| ||||
| H-6′ |
| H-6′ |
| ||||||||
|
| H-1 |
| C-1 |
|
| H-1 |
| C-1 |
| ||
| H-2 | 3.59 | C-2 | 75.8 | H-2 | 3.59 | C-2 | 75.8 | ||||
| H-3 |
| C-3 |
| H-3 |
| C-3 |
| ||||
| H-4 | 3.60 | C-4 | 73.1 | H-4 | 3.62 | C-4 | 73.1 | ||||
| H-5 | 3.65 | C-5 | 79.6 | H-5 | 3.65 | C-5 | 79.7 | ||||
| C-6 | 178.4 | C-6 | 178.4 | ||||||||
|
| H-1 |
| C-1 |
|
| H-1 |
| C-1 |
| ||
| H-2 |
| C-2 |
| H-2 | 3.90 | C-2 | 69.2 | ||||
| H-3 | 4.10 | C-3 | 69.2 | H-3 |
| C-3 |
| ||||
| H-4 |
| C-4 |
| H-4 |
| C-4 |
| ||||
| H-5 | 4.50 | C-5 | 68.9 | H-5 | 4.46 | C-5 | 69.2 | ||||
| H-6 | 1.19 | C-6 | 18.4 | H-6 | 1.19 | C-6 | 18.6 | ||||
I, II, TI, TII, UI, UII are as shown in the structural formula. Values in bold type indicate glycosylated or sulfated positions.
Figure 3The effects of AjFG, dAjFG and oligosaccharides with various dp (Fr-1–Fr-4) on APTT (A), intrinsic FXase (B), and human factor XII activation (C). The results were expressed as mean ± SD (n = 2).
Anticoagulant activity of AjFG, dAjFG, and Fr-1–Fr-4.
| Sample | Mw (kDa) | APTT (μg/mL) a | Anti-FXase (IC50, ng/mL) b |
|---|---|---|---|
| AjFG | 76.4 | 3.06 | 9.20 |
| dAjFG | 3.90 | 26.5 | 189 |
| 4 | 3.49 | 10.3 | 131 |
| 3 | 2.63 | 20.1 | 200 |
| 2 | 1.77 | >128 | >1000 |
| 1 | 0.93 | >128 | >1000 |
| LMWH | 4.50 | 11.3 | 128 |
a The concentration required to double the APTT of human plasma; b IC50 values, the concentration required to inhibit 50% of protease activity.